AssetMemo

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page

Company profile

scPharmaceuticals

Subcutaneous drug-device combination therapeutics (FUROSCIX) -- acquired by MannKind Corporation, Oct 2025

Privately held: no public share price · USA

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Furosemide (subcutaneous, scPharmaceuticals)(FUROSCIX)
Approved
NKCC2Small molecule
Heart Failure

Upcoming events

Unlock with Research ↗
Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Unlock with Research ↗
Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share prices are end-of-day closes, delayed by 24 hours.